References
- Antalis TM, Bugge TH, Wu Q. Membrane-anchored serine proteases in health and disease. Prog Mol Biol Transl Sci 2011;99:1–50
- Miller GS, List K. The matriptase-prostasin proteolytic cascade in epithelial development and pathology. Cell Tissue Res 2013;351:245–53
- List K, Haudenschild CC, Szabo R, et al. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 2002;21:3765–79
- Basel-Vanagaite L, Attia R, Ishida-Yamamoto A, et al. Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase. Am J Hum Genet 2007;80:467–77
- List K, Currie B, Scharschmidt TC, et al. Autosomal ichthyosis with hypotrichosis syndrome displays low matriptase proteolytic activity and is phenocopied in ST14 hypomorphic mice. J Biol Chem 2007;282:36714–23
- Buzza MS, Netzel-Arnett S, Shea-Donohue T, et al. Membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine. Proc Natl Acad Sci USA 2010;107:4200–5
- Netzel-Arnett S, Buzza MS, Shea-Donohue T, et al. Matriptase protects against experimental colitis and promotes intestinal barrier recovery. Inflamm Bowel Dis 2012;18:1303–14
- Uhland K. Matriptase and its putative role in cancer. Cell Mol Life Sci 2006;63:2968–78
- Takeuchi T, Harris JL, Huang W, et al. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000;275:26333–42
- Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000;275:36720–5
- Suzuki M, Kobayashi H, Kanayama N, et al. Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J Biol Chem 2004;279:14899–908
- Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504–16
- Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002;2:289–300
- Shi X, Gangadharan B, Brass LF, et al. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2004;2:395–402
- Milner JM, Patel A, Davidson RK, et al. Matriptase is a novel initiator of cartilage matrix degradation in osteoarthritis. Arthritis Rheum 2010;62:1955–66
- Chen CJ, Wu BY, Tsao PI, et al. Increased matriptase zymogen activation in inflammatory skin disorders. Am J Physiol Cell Physiol 2011;300:C406–15
- Hamilton BS, Gludish DW, Whittaker GR. Cleavage activation of the human-adapted influenza virus subtypes by matriptase reveals both subtype and strain specificities. J Virol 2012;86:10579–86
- Baron J, Tarnow C, Mayoli-Nüssle D, et al. Matriptase, HAT, and TMPRSS2 activate the hemagglutinin of H9N2 influenza A viruses. J Virol 2013;87:1811–20
- Galkin AV, Mullen L, Fox WD, et al. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate 2004;61:228–35
- Steinmetzer T, Schweinitz A, Stürzebecher A, et al. Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem 2006;49:4116–26
- Uhland K, Siphos B, Arkona C, et al. Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma. Int J Oncol 2009;35:347–57
- Zoratti GL, Tanabe LM, Varela FA, et al. Targeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling. Nat Commun 2015;6:6776
- Colombo E, Desilets A, Duchene D, et al. Design and synthesis of potent, selective inhibitors of matriptase. ACS Med Chem Lett 2012;3:530–4
- Han Z, Harris PK, Jones DE, et al. Inhibitors of HGFA, matriptase, and hepsin serine proteases: a nonkinase strategy to block cell signaling in cancer. ACS Med Chem Lett 2014;5:1219–24
- Goswami R, Mukherjee S, Wohlfahrt G, et al. Discovery of pyridyl bis(oxy)dibenzimidamide derivatives as selective matriptase inhibitors. ACS Med Chem Lett 2013;4:1152–7
- Goswami R, Wohlfahrt G, Mukherjee S, et al. Discovery of O-(3-carbamimidoylphenyl)-l-serine amides as matriptase inhibitors using a fragment-linking approach. Bioorg Med Chem Lett 2015;25:616–20
- Sisay MT, Steinmetzer T, Stirnberg M, et al. Identification of the first low-molecular-weight inhibitors of matriptase-2. J Med Chem 2010;53:5523–35
- Lila C, Gloanec P, Cadet L, et al. Large scale preparation of protected 4-aminomethylbenzamidine. application to the synthesis of the thrombin inhibitor, Melagatran. Chem Commun 1997;28:4419–29
- Gustafsson D, Bylund R, Antonsson T, et al. A new oral anticoagulant: the 50-year challenge. Nat Rev Drug Discov 2004;3:649–59
- Schweinitz A, Steinmetzer T, Banke IJ, et al. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem 2004;279:33613–22
- Stürzebecher A, Dönnecke D, Schweinitz A, et al. Highly potent and selective substrate analogue factor Xa inhibitors containing D-homophenylalanine analogues as P3 residue: part 2. ChemMedChem 2007;2:1043–53
- Kadono S, Sakamoto A, Kikuchi Y, et al. Structure-based design of P3 moieties in the peptide mimetic factor VIIa inhibitor. Biochem Biophys Res Commun 2005;327:589–96
- Saupe SM, Steinmetzer T. A new strategy for the development of highly potent and selective plasmin inhibitors. J Med Chem 2012;55:1171–80
- Hellstern P, Stürzebecher U, Wuchold B, et al. Preservation of in vitro function of platelets stored in the presence of a synthetic dual inhibitor of factor Xa and thrombin. J Thromb Haemost 2007;5:2119–26
- Becker GL, Sielaff F, Than ME, et al. Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. J Med Chem 2010;53:1067–75
- Kauer J. P-Benzoyl-L-phenylalanine, a new photoreactive amino acid. Photolabeling of calmodulin with a synthetic calmodulin-binding peptide. J Biol Chem 1986;261:10695–700
- Meyer D, Sielaff F, Hammami M, et al. Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation. Biochem J 2013;452:331–43
- Walsmann P. On the purification of thrombin preparations. Pharmazie 1968;23:401–2
- Hammami M, Rühmann E, Maurer E, et al. New 3-amidinophenylalanine-derived inhibitors of matriptase. MedChemComm 2012;3:807–13
- Dixon M. The determination of enzyme inhibitor constants. Biochem J 1953;55:170–1
- Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Meth Enzymol 1997;276:307–26
- Brandt T, Holzmann N, Muley L, et al. Congeneric but still distinct: how closely related trypsin ligands exhibit different thermodynamic and structural properties. J Mol Biol 2011;405:1170–87
- Collaborative Computational Project Number 4.The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 1994;50:760–3
- Adams PD, Afonine PV, Bunkoczi G, et al. PHENIX: a comprehensive python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 2010;66:213–21
- Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004;60:2126–32
- Bode W, Mayr I, Baumann U, et al. The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 1989;8:3467–75
- Tziridis A, Rauh D, Neumann P, et al. Correlating structure and ligand affinity in drug discovery: a cautionary tale involving second shell residues. Biol Chem 2014;395:891–903
- Chemical Computing Group. MOE, version 2014.9, 32 bit. Montreal, Canada
- Sielaff F, Böttcher-Friebertshäuser E, Meyer D, et al. Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT. Bioorg Med Chem Lett 2011;21:4860–4
- Biela A, Sielaff F, Terwesten F, et al. Ligand binding stepwise disrupts water network in thrombin: enthalpic and entropic changes reveal classical hydrophobic effect. J Med Chem 2012;55:6094–110
- Böttcher-Friebertshäuser E, Freuer C, Sielaff F, et al. Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors. J Virol 2010;84:5605–14
- Schweinitz A, Stürzebecher A, Stürzebecher U, et al. New substrate analogue inhibitors of factor Xa containing 4-amidinobenzylamide as P1 residue: part 1. Med Chem 2006;2:349–61
- Tucker TJ, Lumma WC, Mulichak AM, et al. Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site. J Med Chem 1997;40:830–2
- Steinmetzer T, Dönnecke D, Korsonewski M, et al. Modification of the N-terminal sulfonyl residue in 3-amidinophenylalanine-based matriptase inhibitors. Bioorg Med Chem Lett 2009;19:67–73